Taken together, this allows us to put forward the hypothesis that sclerostin, originating from excessive local production in calcified vessels, may spill over to the serum by which it may prevent further progression of (vascular) calcifications and contribute to the high incidence of low bone turnover in CKD patients [15]. The gene discussed is SOST; the disease is chronic kidney disease.